Journal of Diabetes Research / 2018 / Article / Fig 1

Research Article

Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes

Figure 1

CONSORT flow diagram. A total of 12 patients were recruited in two different clinical studies ( each study) using different doses and administration of GAD-alum. None of the patients were excluded during these trials’ follow-up.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.